1. Sobin, L. H. and Wittekind, C.h. (2002). TNM Classification of Malignant Tumours ,Wiley-Liss,New York.
2. Zhang, S. , Zhang, H. S. , Reuter, V. E. , Slovin, S. F. , Scher, H. I. and Livingston, P. O. (1998).Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.Clinical Cancer Research 4,295–302.
3. WORLD HEALTH ORGANIZATION (1994).Evaluation of carcinogenic risk to humans. Schistosomes, liver flukes and Helicobacter pylori .IARC Monograph 61,45–119.
4. Barranco, S. C. , Townsend, C. M. J. , Casartelli, C. , Macik, B. G. , Burger, N. L. , Boerwinkle, W. and Gourley, W. K. (1983).Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach.Cancer Research 43,1703–1709.
5. van Dam, G. J. , Claas, F. H. , Yazdanbakhsh, M. , Kruize, Y. C. , van Keulen, A. C. , Ferreira, S. T. , Rotmans, J. P. and Deelder, A. M. (1996). Schistosoma mansoni excretory circulating cathodic antigen shares Lewis-x epitopes with a human granulocyte surface antigen and evokes host antibodies mediating complement-dependent lysis of granulocytes.Blood 88,4246–4251.